Nasdaq auph.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced ...

Nasdaq auph. Things To Know About Nasdaq auph.

It has been quite some time since we last took a look at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). This small biopharma has been somewhat of a roller coaster ride for its shareholders in recent ...Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ... Anyone who held Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) over the last year knows what a loser feels like. The share price has slid 66% in that time. On the bright side, the stock is actually up 50%AUPH Inverse H&S Price has broken out of a down channel I see this breaking down slightly back into the channel, forming a right shoulder along the yellow horizontal and then continuing to pursue the reversal above the channel Lets see what happens on this Weekly chart Bars pattern in green shows my idea Price has broken out of a down channel I see this breaking down slightly back into the ... AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...

The new research reports from Fundamental Markets, available for free download at the links above, examine B Communications Ltd. (NASDAQ:BCOM), Student Transportation Inc (NASDAQ:STB), Aurinia ...Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Intra-Cellular Therapies Inc ...

8.82%. 141,687,578. 12,497,875. 1,990,667. 6.28. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Aurinia Pharmaceuticals gives investors a sense of ...

Sep 18, 2023 · What happenedAurinia Pharmaceuticals (NASDAQ: AUPH), a company focused on developing treatments for autoimmune diseases, saw its share price fall by more than 5% in early trading on Monday. The ... See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. AUPH's current price target is …Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. The first program, AUR200, was acquired from privately-held ...Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced a supportive interim analysis of its AURORA 2 continuation study evaluating Lupkynis (voclosporin) in lupus nephritis.; Data will be ...

Jul 3, 2023 · Aurinia Pharmaceuticals AUPH rose almost 5.8% on Jun 30, as management announced that it is exploring strategic alternatives for the company’s future. AUPH will consider a range of options ...

During the last session, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares were 2.07 million, with the beta value of the company hitting 1.26. At the end of the trading day, the stock’s price was $8.64, reflecting an intraday gain of 0.47% or $0.04. The 52-week high for the AUPH share is ...

Aurinia Pharma (NASDAQ:AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus Revenue ...The new research reports from Fundamental Markets, available for free download at the links above, examine B Communications Ltd. (NASDAQ:BCOM), Student Transportation Inc (NASDAQ:STB), Aurinia ...Shares of Aurinia Pharmaceuticals Inc. AUPH gained 13.2% on Dec 2, following fresh rumors of a potential buyout. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on ...Find the latest news headlines from Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.Aurinia Pharmaceuticals (NASDAQ: AUPH), in its third-quarter earnings call for 2023, reported a significant increase in net product revenue and ongoing expansion efforts, while also revealing that ...Nov 29, 2023 · 2 analysts have issued twelve-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $13.00 to $15.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 62.8% from the stock's current price. View analysts price targets for AUPH or ...

AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH): Supportive interim analysis of its AURORA 2 Phase 3 continuation study that is evaluating Lupkynis for the treatment of lupus nephritis.Dec 4, 2023 · AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ... Aurinia Pharmaceuticals (NASDAQ:AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical …EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr ...

Market Capitalization. $1.24 billion. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $14.00. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ...

Mar 9, 2023 · 9.24. +0.64. +7.44%. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Greetings, and welcome to the Aurinia Pharmaceuticals Fourth Quarter ... Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Dec 4, 2023 · Year-to-date, Rivian Automotive Inc shares have moved -4.45%, while the 5-day performance has seen it change 5.70%. Over the past 30 days, the shares of Rivian Automotive Inc (NASDAQ:RIVN) have changed 0.11%. Short interest in the company has seen 103.62 million shares shorted with days to cover at 2.62. Wall Street analysts have a consensus ... Nov 17, 2023 · msn.com - August 8 at 2:56 PM. Jump Financial LLC Takes $366,000 Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) marketbeat.com - August 8 at 5:21 AM. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) to Post Q1 2024 Earnings of ($0.14) Per Share, Leerink Partnrs Forecasts. marketbeat.com - August 7 at 7:47 AM. To wit, the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) share price is 78% higher than it was a year ago, much better than the market return of around 12% (not including dividends) in the same ...H.C. Wainwright analyst Ed Arce maintained a Buy rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) on Friday, setting a price target of $35, which is approximately 142.38% above the present share ...Aurinia Pharmaceuticals (NASDAQ:AUPH) Third Quarter 2022 ResultsKey Financial Results. Revenue: US$55.8m (up 280% from 3Q 2021). Net loss: US$8.99m (loss narrowed by 82% from 3Q 2021). US$0.063 ...Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares stood at 0.69 million during the latest session, with the company’s beta value hitting 1.28. At the last check today, the stock’s price was $9.28, to imply an increase of 2.66% or $0.24 in intraday trading.In trading on Thursday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) crossed above their 200 day moving average of $8.57, changing hands as high as $8.92 per share. Aurinia Pharmaceuticals ...Shares of NASDAQ AUPH opened at $9.06 on Monday. The company has a current ratio of 5.77, a quick ratio of 5.33 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.07 and a twelve month high of $12.43. The stock has a 50 day moving average of $7.93 and a two-hundred day moving average of $9.20.

Back to AUPH Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ...

Aurinia Pharmaceuticals saw a decline in short interest in October. As of October 31st, there was short interest totaling 17,280,000 shares, a decline of 0.9% from the previous total of 17,430,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that ...

SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7 ...8.82%. 141,687,578. 12,497,875. 1,990,667. 6.28. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Aurinia Pharmaceuticals gives investors a sense of ...Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ...Aurinia Pharmaceuticals (NASDAQ:AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ...Moderna, Inc. (NASDAQ:MRNA) announced initial data from its Phase 2 study showing that a single 50 µg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals ...Aurinia Pharmaceuticals 22.3 mln share stock offering priced at $6.75, 36% below Monday's closing price. Mar. 14, 2017 at 8:04 a.m. ET by Tomi Kilgore.AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...Sep 18, 2023 · What happenedAurinia Pharmaceuticals (NASDAQ: AUPH), a company focused on developing treatments for autoimmune diseases, saw its share price fall by more than 5% in early trading on Monday. The ...

NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ... SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7 ...Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Playstudios, Twitter, Aurinia, and Stronghold and Encourages Investors to Contact the FirmOcular Therapeutix Inc (NASDAQ:OCUL) has a beta value of 0.88 and has seen 1.29 million shares traded in the recent trading session. The company, currently valued at $262.48M, closed the recent trade at $3.31 per share which meant it gained $0.63 on the day or 23.32% during that session. ... (NASDAQ:AUPH) has a beta value of 1.39 and …Instagram:https://instagram. otcmkts pcrfybest financial advisors san franciscowill apple stock go up this weeksp 400 Shares of Aurinia Pharmaceuticals Inc. AUPH gained 13.2% on Dec 2, following fresh rumors of a potential buyout. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on ... cryptocurrency applicationshow to test if gold is real at home Aurinia Pharmaceuticals (NASDAQ:AUPH) has been subject to buyout speculations for well over a year now. It was as early as May 2021, when The Times mentioned AstraZeneca ( AZN ) or GSK ( GSK ) are ...Aurinia Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AUPH) $8.60 -0.09 (-1.04%) (As of 11/29/2023 ET) Compare Today's Range $8.54 $8.99 50-Day … wes price Aurinia Pharmaceuticals Inc's (NASDAQ:AUPH) ... Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) is scheduled to host a virtual event on Tuesday, Jan. 26, from 8 a.m. to 10 a.m. to provide an update on ...Dec 4, 2023 · Year-to-date, Rivian Automotive Inc shares have moved -4.45%, while the 5-day performance has seen it change 5.70%. Over the past 30 days, the shares of Rivian Automotive Inc (NASDAQ:RIVN) have changed 0.11%. Short interest in the company has seen 103.62 million shares shorted with days to cover at 2.62. Wall Street analysts have a consensus ...